Management of bulky high-grade pleomorphic sarcoma using grid therapy technique
Authors
Abstract:
In the present study, a case was reported concerning a patient with a bulky extremity soft tissue sarcoma treated with spatially fractionated Grid therapy and then followed by standard external beam radiotherapy. Treatment was performed using a Grid block to deliver 15 Gy in one fraction. There was one week interval break before EBRT treatment with 50 Gy in 25 fractions for the neoadjuvant external beam radiotherapy. The surgery was performed 4 weeks after the completion of radiotherapy. The follow-up time was considered as 24 months. The patientchr('39')s general condition was good during this period without the presence of tumor recurrence or grade 3 or 4 treatment-related toxicities. Combining different treatment techniques like grid therapy is feasible and may improve the outcomes in the management of bulky high-grade soft-tissue sarcomas of the extremities.
similar resources
Management of high-grade pleomorphic sarcoma with colon metastasis
Soft tissue sarcomas (STS) are a heterogeneous group of tumors of mesenchymal origin that represent a rare form of adult malignancy. According to the World Health Organization classification system, there are more than 100 histologic subtypes of sarcoma based on tissue of origin. Staging criteria most commonly use the American Joint Committee on Cancer’s TNM Classification of Malignant Tumours....
full textA case of mediastinum undifferentiated high grade pleomorphic sarcoma.
Primary anterior mediastinum undifferentiated high grade pleomorphic sarcoma is rare that most physician including thoracic surgeon would not experience this disease. Huge anterior mediastinum tumor pressed the heart and it invaded into the left pulmonary arterial trunk. We did the mediastinum tumor resection, left pneumonectomy and left phrenic, sympathetic and vagus nerve merger excision. But...
full textHigh-Grade Left Atrial Pleomorphic Sarcoma: Case Report and Review
Primary pleomorphic sarcoma of the left atrium is a rare tumor. There is no actual evidence of the management of this pathological entity, so the main treatment is individualized, surgical management being the cornerstone of the treatment. We present a 78-year-old female who had a clinical picture of heart failure, documenting an atrial mass of the left atrium, with high-grade pleomorphic sarco...
full textHead and Neck Tumors: Management of Primary Undifferentiated Pleomorphic Sarcoma
Introduction: Sarcomas account for 1% of all tumors originated in the head and neck regions in adults. They constitute a heterogeneous group of tumors of mesenchymal origin with multiple histological variants. The undifferentiated pleomorphic sarcoma (UPS) subtype is the most frequent variant with an incidence range of 2.7-38%. Materials and Methods: This retrospective...
full text[Undifferentiated high-grade pleomorphic sarcoma of the orbit: a case report].
CASE REPORT A 27-year-old female presented to us with a complaint of proptosis of her right eye. Imaging tests showed an extraconal mass in the medial orbital wall, which affected the medial rectus. The tumor was removed and adjuvant radiotherapy was required. The histological examination showed an undifferentiated high-grade pleomorphic sarcoma of the orbit. There has not been recurrence after...
full textExperimental murine model of primary high grade undifferentiated pleomorphic sarcoma not otherwise specified.
BACKGROUND Undifferentiated pleomorphic sarcoma not otherwise specified (NOS) is a malignant neoplasm of uncertain origin arising both in the soft tissue and the bone. The WHO classified this tumour in 2002 but controversy has plagued this entity due to limited availability of tissue for study. The aim of this study was to establish a reproducible xenograft model of primary human undifferentiat...
full textMy Resources
Journal title
volume 19 issue 1
pages 239- 242
publication date 2021-01
By following a journal you will be notified via email when a new issue of this journal is published.
Hosted on Doprax cloud platform doprax.com
copyright © 2015-2023